Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
100 hedge funds and large institutions have $856M invested in Avadel Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 17 closing their positions.
93% more capital invested
Capital invested by funds: $443M → $856M (+$413M)
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
8% more funds holding
Funds holding: 93 → 100 (+7)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
7% less call options, than puts
Call options by funds: $21.6M | Put options by funds: $23.1M
9.35% less ownership
Funds ownership: 77.02% → 67.68% (-9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$34.8M |
| 2 |
RI
RTW Investments
New York
|
+$13.9M |
| 3 |
Janus Henderson Group
London,
|
+$9.04M |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$6.5M |
| 5 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$6.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$13.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.44M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.74M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.4M |
| 5 |
ACM
Altium Capital Management
New York
|
-$4.58M |
AVDL Hedge Fund Activity: Q2 2023 in Review
100 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2023, worth a combined $856M — up 93% from $443M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AVDL positions and 17 closed out — a net gain of 7 holders — while 34 added to existing stakes and 24 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $34.8M. The largest seller was Cowen and Company, cutting an estimated $13.9M.
- 100 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2023, up from 93 in Q1 2023.
- Funds reported $856M of Avadel Pharmaceuticals stock for Q2 2023, up 93% quarter-over-quarter.
- 24 funds opened new Avadel Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +7 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $34.8M added.
- The largest Avadel Pharmaceuticals seller in Q2 2023 was Cowen and Company, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2023.